News coverage about Motus GI (NASDAQ:MOTS) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Motus GI earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.9127244337019 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
MOTS has been the topic of several research reports. Piper Jaffray initiated coverage on Motus GI in a research note on Sunday, March 11th. They set an “overweight” rating and a $7.00 price target on the stock. ValuEngine lowered Motus GI from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Finally, Oppenheimer initiated coverage on Motus GI in a research note on Monday, March 12th. They set an “outperform” rating and a $7.00 price target on the stock.
Shares of MOTS traded down $0.06 during trading hours on Friday, hitting $4.45. 7,683 shares of the stock traded hands, compared to its average volume of 37,727. Motus GI has a 1-year low of $3.75 and a 1-year high of $5.30. The firm has a market capitalization of $70.20 and a PE ratio of -3.48.
In related news, Chairman David P. Hochman bought 115,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were purchased at an average price of $5.00 per share, with a total value of $575,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark Pomeranz bought 8,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $40,000.00. The disclosure for this purchase can be found here. Insiders have bought 1,175,000 shares of company stock worth $5,875,000 in the last ninety days.
ILLEGAL ACTIVITY NOTICE: “Motus GI (MOTS) Receives Daily Media Sentiment Score of 0.09” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/motus-gi-mots-receives-daily-media-sentiment-score-of-0-09.html.
Motus GI Company Profile
Motus GI Holdings, Inc, a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.